The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …

The introduction of selective tyrosine-kinase inhibitors (TKIs) for the treatment of chronic
myeloid leukaemia has changed patient outcome and, consequently, management of this …

In the present study, we address the issue of the discontinuation of imatinib mesylate
(Gleevec) in chronic myelogenous leukemia with undetectable residual disease for more …

Chronic myeloid leukemia (CML) has become a model in research and management among
malignant disorders. Since the discovery of the presence of a unique and constant …

Summary Abstract Imatinib (Gleevec®, Glivec®) is a synthetic tyrosine kinase inhibitor used
in the treatment of chronic myeloid leukaemia (CML). It is specifically designed to inhibit the …

Purpose: In the first years of imatinib treatment, BCR-ABL remained detectable in all but a
small minority of patients with chronic myeloid leukemia. We determined whether BCR-ABL …

Purpose: Review the state-of-art knowledge of the biology and therapy of chronic
myelogenous leukemia (CML). Experimental Design: A review of the literature was …

Patients in “late” first chronic phase. It should be noted that the requirements for a
progression protective response are much more stringent in patients with chronic phase …

Since protein kinases are frequently mutated or otherwise deregulated in human
malignancies, they serve as a target for differentiating between tumor cells and normal …

For chronic phase chronic myeloid leukemia (CML) patients treated with imatinib, the
essential pre-therapy assessments include bone marrow morphology and cytogenetics as …